Genetics testing company 23andMe has filed for Chapter 11 bankruptcy protection and launched a sale process, just weeks after rejecting a takeover offer from co-founder and CEO Anne Wojcicki.
Why it matters: The writing was on the wall when 23andMe's independent directors quit last fall, but it's still stunning to witness the dysfunctional destruction of the rare biotech unicorn to become a household name.
